Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
345 hedge funds and large institutions have $5.86B invested in Blueprint Medicines in 2024 Q4 according to their latest regulatory filings, with 60 funds opening new positions, 148 increasing their positions, 99 reducing their positions, and 28 closing their positions.
114% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 28
49% more repeat investments, than reductions
Existing positions increased: 148 | Existing positions reduced: 99
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
13% more call options, than puts
Call options by funds: $148M | Put options by funds: $131M
8% more funds holding
Funds holding: 319 → 345 (+26)
2.59% more ownership
Funds ownership: 103.12% → 105.71% (+2.6%)
3% less capital invested
Capital invested by funds: $6.04B → $5.86B (-$189M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$109M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$52.4M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$47M |
| 4 |
Jennison Associates
New York
|
+$33M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$30.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$208M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$77.2M |
| 3 |
Man Group
London,
United Kingdom
|
-$38M |
| 4 |
State Street
Boston,
Massachusetts
|
-$24.3M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$23M |
BPMC Hedge Fund Activity: Q4 2024 in Review
345 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q4 2024, worth a combined $5.86B — down 3.1% from $6.04B a quarter earlier.
Buyers outnumbered sellers: 60 funds opened new BPMC positions and 28 closed out — a net gain of 32 holders — while 148 added to existing stakes and 99 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $109M. The largest seller was Fidelity Investments, cutting an estimated $208M.
- 345 institutional investors held Blueprint Medicines (BPMC) as of Q4 2024, up from 319 in Q3 2024.
- Funds reported $5.86B of Blueprint Medicines stock for Q4 2024, down 3.1% quarter-over-quarter.
- 60 funds opened new Blueprint Medicines positions in Q4 2024 and 28 closed out, a net change of +32 holders.
- The largest Blueprint Medicines buyer in Q4 2024 was Avoro Capital Advisors, an estimated $109M added.
- The largest Blueprint Medicines seller in Q4 2024 was Fidelity Investments, an estimated $208M sold.
Based on aggregated 13F filings for Q4 2024.